B Braun, the German privately-owned provider of pharmaceuticals and medical goods including infusion and electrolyte solutions, has acquired Gematek in Tver, 170 km north-east of Moscow, from IFD Kapital, a Russian investment firm. Gematek was initially IFD Kapital's investment project to build a production facility for infusion solutions based on the latest technologies and standards. Financial details of the deal have not been released, but IFD Kapital said that its financial return exceeded almost twice its investments in the project; Russian experts estimate the deal was worth around $2 million. B Braun, which had been operating in Russia for a few years, believes the deal will strengthen its position on the local market and help to save funds currently spent on transportation of its products from Germany. The company has more than 27,000 employees in 140 subsidiaries in almost 50 countries.
B Braun of Germany buys plant in Russia
B Braun, the German privately-owned provider of pharmaceuticals and medical goods including infusion and electrolyte solutions, has acquired Gematek in Tver, 170 km north-east of Moscow, from IFD Kapital, a Russian investment firm. Gematek was initially IFD Kapital's investment project to build a production facility for infusion solutions based on the latest technologies and standards. Financial details of the deal have not been released, but IFD Kapital said that its financial return exceeded almost twice its investments in the project; Russian experts estimate the deal was worth around $2 million. B Braun, which had been operating in Russia for a few years, believes the deal will strengthen its position on the local market and help to save funds currently spent on transportation of its products from Germany. The company has more than 27,000 employees in 140 subsidiaries in almost 50 countries.
More from Deals
More from Business
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.